These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32778162)

  • 1. CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance.
    Aslam B; Rasool M; Idris A; Muzammil S; Alvi RF; Khurshid M; Rasool MH; Zhang D; Ma Z; Baloch Z
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):131. PubMed ID: 32778162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas system, antibiotic resistance and virulence in bacteria: Through a common lens.
    Roy S; Naha S; Rao A; Basu S
    Prog Mol Biol Transl Sci; 2021; 178():123-174. PubMed ID: 33685595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.
    Rafiq MS; Shabbir MA; Raza A; Irshad S; Asghar A; Maan MK; Gondal MA; Hao H
    BioDrugs; 2024 May; 38(3):387-404. PubMed ID: 38605260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizing pathogens to antibiotics using the CRISPR-Cas system.
    Goren M; Yosef I; Qimron U
    Drug Resist Updat; 2017 Jan; 30():1-6. PubMed ID: 28363331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.
    Wu Y; Battalapalli D; Hakeem MJ; Selamneni V; Zhang P; Draz MS; Ruan Z
    J Nanobiotechnology; 2021 Dec; 19(1):401. PubMed ID: 34863214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.
    Gholizadeh P; Aghazadeh M; Asgharzadeh M; Kafil HS
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2043-2051. PubMed ID: 28601970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of CRISPR in evolution analysis, detecting and typing, virulence and antibiotic resistance regulation in food-borne pathogens].
    Bai Z; Wang W; Ji X; Xiao Y; Zhang S; Wang Z; Li H; Dong Q
    Sheng Wu Gong Cheng Xue Bao; 2021 Jul; 37(7):2414-2424. PubMed ID: 34327906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide correlation analysis suggests different roles of CRISPR-Cas systems in the acquisition of antibiotic resistance genes in diverse species.
    Shehreen S; Chyou TY; Fineran PC; Brown CM
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180384. PubMed ID: 30905286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens.
    Shabbir MAB; Shabbir MZ; Wu Q; Mahmood S; Sajid A; Maan MK; Ahmed S; Naveed U; Hao H; Yuan Z
    Ann Clin Microbiol Antimicrob; 2019 Jul; 18(1):21. PubMed ID: 31277669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas is associated with fewer antibiotic resistance genes in bacterial pathogens.
    Pursey E; Dimitriu T; Paganelli FL; Westra ER; van Houte S
    Philos Trans R Soc Lond B Biol Sci; 2022 Jan; 377(1842):20200464. PubMed ID: 34839714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.
    Mayorga-Ramos A; Zúñiga-Miranda J; Carrera-Pacheco SE; Barba-Ostria C; Guamán LP
    ACS Infect Dis; 2023 Jul; 9(7):1283-1302. PubMed ID: 37347230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance.
    Abavisani M; Khayami R; Hoseinzadeh M; Kodori M; Kesharwani P; Sahebkar A
    Drug Resist Updat; 2023 May; 68():100948. PubMed ID: 36780840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci.
    Rodrigues M; McBride SW; Hullahalli K; Palmer KL; Duerkop BA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31527030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Gene Editing to Biofilm Busting: CRISPR-CAS9 Against Antibiotic Resistance-A Review.
    Pandey P; Vavilala SL
    Cell Biochem Biophys; 2024 Jun; 82(2):549-560. PubMed ID: 38702575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance.
    Gholizadeh P; Köse Ş; Dao S; Ganbarov K; Tanomand A; Dal T; Aghazadeh M; Ghotaslou R; Ahangarzadeh Rezaee M; Yousefi B; Samadi Kafil H
    Infect Drug Resist; 2020; 13():1111-1121. PubMed ID: 32368102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in gene-editing approaches for tackling antibiotic resistance threats: a review.
    Al-Fadhli AH; Jamal WY
    Front Cell Infect Microbiol; 2024; 14():1410115. PubMed ID: 38994001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driving to Safety: CRISPR-Based Genetic Approaches to Reducing Antibiotic Resistance.
    Bier E; Nizet V
    Trends Genet; 2021 Aug; 37(8):745-757. PubMed ID: 33745750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterococcus faecalis CRISPR-Cas Is a Robust Barrier to Conjugative Antibiotic Resistance Dissemination in the Murine Intestine.
    Price VJ; McBride SW; Hullahalli K; Chatterjee A; Duerkop BA; Palmer KL
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31341074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.
    Bikard D; Euler CW; Jiang W; Nussenzweig PM; Goldberg GW; Duportet X; Fischetti VA; Marraffini LA
    Nat Biotechnol; 2014 Nov; 32(11):1146-50. PubMed ID: 25282355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CRISPR-Cas systems as weapons against pathogenic bacteria].
    Bikard D; Barrangou R
    Biol Aujourdhui; 2017; 211(4):265-270. PubMed ID: 29956653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.